Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Unravelling the benefit against the risk of long-term dual antiplatelet therapy.

Bolognese L, Angiolillo DJ.

Curr Opin Cardiol. 2011 Dec;26 Suppl 1:S22-30. doi: 10.1097/01.hco.0000409964.20588.8c. Review.

PMID:
22129580
2.

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.

Mehta SR, Yusuf S.

J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):79S-88S. Review.

PMID:
12644345
3.

The role of clopidogrel in the management of acute coronary syndromes.

Wodlinger AM, Pieper JA.

Clin Ther. 2003 Aug;25(8):2155-81. Review.

PMID:
14512126
4.

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP.

Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Review.

PMID:
18319394
5.

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.

Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial.

Circulation. 2004 Sep 7;110(10):1202-8. Epub 2004 Aug 16.

6.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
7.
8.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
9.

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee.

Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022.

PMID:
20598967
10.

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators.

Am Heart J. 2006 Oct;152(4):627-35.

PMID:
16996826
11.

Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.

Bowry AD, Brookhart MA, Choudhry NK.

Am J Cardiol. 2008 Apr 1;101(7):960-6. doi: 10.1016/j.amjcard.2007.11.057. Epub 2008 Feb 11. Review.

PMID:
18359315
12.

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.

Ho WK, Hankey GJ, Eikelboom JW.

Expert Opin Pharmacother. 2004 Mar;5(3):493-503. Review.

PMID:
15013918
13.

Antiplatelet options for secondary prevention in acute coronary syndromes.

Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G.

Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1403-15. doi: 10.1586/erc.11.139. Review.

PMID:
22059790
14.

Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.

Zeymer U, Gitt A, J√ľnger C, Bauer T, Heer T, Koeth O, Mark B, Zahn R, Senges J, Gottwik M.

Thromb Haemost. 2008 Jan;99(1):155-60. doi: 10.1160/TH07-09-0556.

PMID:
18217148
15.

What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?

Steinhubl S, Berger P.

Am Heart J. 2003 Jun;145(6):971-8. Review.

PMID:
12796751
16.

Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.

Zusman RM, Chesebro JH, Comerota A, Hartmann JR, Massin EK, Raps E, Wolf PA.

Clin Cardiol. 1999 Sep;22(9):559-73. Review.

17.

Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.

Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-Matula J, Huber K.

Thromb Haemost. 2010 Dec;104(6):1211-8. doi: 10.1160/TH10-04-0218. Epub 2010 Oct 12.

PMID:
20941464
18.

Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.

DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, Lam L, McGowan C, Lee G, DeCaro M, Ruggiero N, Singhal S, Greenspon A.

Pharmacotherapy. 2007 May;27(5):691-6.

PMID:
17461704
19.

Clinical use of clopidogrel in acute coronary syndrome.

Zambahari R, Kwok OH, Javier S, Mak KH, Piyamitr S, Tri Ho HQ, Hwang JJ, Suryawan R, Chow WH.

Int J Clin Pract. 2007 Mar;61(3):473-81. Review.

20.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

Supplemental Content

Support Center